News Formal

MedTech Earnings in the Age of Ozempic May Not Be That Bad

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

The September quarter saw the biggest plunge in medical-device stocks since 2020s lockdowns. Dragging them were fears that new weight-loss drugs will slash demand for devices that treat diabetes, sleep problems, and other weight-related conditions.

Sour sentiment on device stocks has compelled Petrone and most other medtech analysts to reduce their price targets. But feedback from doctors convinces him that September-quarter sales and earnings for most of the companies will be okay. The Mizuho analyst doesn’t cover diabetes-device stocks such as DexCom and Insulet that have suffered some of the steepest selloffs. Businesses that treat sleep apnea also lost favor, and the analyst thinks that investors could be pleasantly surprised by September results from ResMed and Inspire Medical Systems . He rates both shares at Buy.

September-quarter sales volumes were also good for ResMed, Petrone believes. In the long term, weight-loss drugs may cut demand, but he figures ResMed will show sales of $4.6 billion, and earnings per share of $7.04, when it reports on Oct. 26.

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 3. in SE
 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Källa: NBCLA - 🏆 319. / 59 Läs mer »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Källa: NBCNewYork - 🏆 270. / 63 Läs mer »